Latest Cancer News

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (07-27-2016)
The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (07-26-2016)
In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (07-21-2016)
Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

More Cancer News

Locations

COLCHESTER
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
792 College Parkway, Suite 207
Colchester, Vermont   05446
TEL: (802) 655-3400
FAX: (802) 655-9170

ST ALBANS
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
4 Crest Road,
St. Albans, VT 05478
TEL: (802) 524-0537
FAX: (802) 524-0538

MIDDLEBURY
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
110 Porter Drive,
Middlebury, VT 05753
TEL: (802) 388-8977
FAX: (802) 388-8976